ATLANTA, April 15 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE: CRY), an implantable biological medical device and
cardiovascular tissue processing company, announced today that 2010
first quarter financial results will be released on Wednesday, April 28, 2010. On that day, the
Company will hold a teleconference call and live webcast at
10:00 a.m. Eastern Time to discuss
the results, followed by a question and answer session hosted by
Steven G. Anderson, president and
chief executive officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 10:00 a.m.
A replay of the teleconference will be available April 28 through May 5 and can be accessed by
calling (toll free) 877-660-6853 or 201-612-7415. The account
number for the replay is 244 and the conference number is
349352.
The live webcast and replay can be accessed by going to the
Investor Relations section of the CryoLife web site at
www.cryolife.com and selecting the heading Webcasts &
Presentations.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. The Company's
CryoValve® SG pulmonary heart valve, processed using
CryoLife's proprietary SynerGraft® technology, has FDA
510(k) clearance for the replacement of diseased, damaged,
malformed, or malfunctioning native or prosthetic pulmonary valves.
The Company's CryoPatch® SG pulmonary cardiac
patch has FDA 510(k) clearance for the repair or reconstruction of
the right ventricular outflow tract (RVOT), which is a surgery
commonly performed in children with congenital heart defects, such
as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.
CryoPatch SG is distributed in three anatomic configurations:
pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.
The Company's BioGlue® Surgical Adhesive is FDA
approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is
also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair.
The Company's BioFoam™ Surgical Matrix is CE marked in the
European Community for use as an adjunct in the sealing of
abdominal parenchymal tissues (liver and spleen) when cessation of
bleeding by ligature or other conventional methods is ineffective
or impractical. BIOGLUE Aesthetic®
Medical Adhesive is CE marked in the European Community for
periosteal fixation following endoscopic browplasty (brow lift) in
reconstructive plastic surgery and is distributed by a third party
for this indication. CryoLife distributes
HemoStase®, a hemostatic agent, in much of the U.S. for
use in cardiac and vascular surgery and in many international
markets for cardiac, vascular, and general surgery, subject to
certain exclusions.
For additional information about the company, visit CryoLife's
Web site:
http://www.cryolife.com.
Media Contacts:
D. Ashley Lee
Executive Vice President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355
Nina Devlin
Edelman
Phone: 212-704-8145
SOURCE CryoLife, Inc.